Introduction
Methods
General outline of the PMSP in Flanders
Two pathways of PMSP participation
Population
-
actively opted out;
-
already had a PMSP screening in the previous year;
-
were already invited in the previous year;
-
had a pathway-1-screening in the current year.
Opportunistic screening in Flanders
Oncological follow-up of screenings
Determining screening status
-
Invitation response
-
Percentage of women who got a PMSP screening within 24 months after receiving their invitation (The invitation is valid up to 24 months after being sent).
-
-
Coverage
-
The basis of our coverage data was the eligible population. Since the eligible population fluctuates throughout the year (death, immigration, etc.), we used the data of the first of January of each year as the basis for coverage data. The Flemish Working Group on breast cancer screening developed a method to determine coverage status for all of these women: check for opportunistic screening and PMSP screening in year x and x-1 and then use Table 1 to categorise. Data on opportunistic screening coverage cannot be reliably calculated for 2002.
-
Screening year x-1 | Screening year x | Coverage year x |
---|---|---|
No screening | No screening | No coverage |
PMSP | PMSP coverage | |
Opportunistic | Opportunistic coverage | |
PMSP & Opportunistic | PMSP coverage | |
Opportunistic | No screening | Opportunistic coverage |
PMSP | ||
Opportunistic | ||
PMSP & Opportunistic | ||
PMSP | No screening | PMSP coverage |
Opportunistic | ||
Opportunistic & PMSP | No screening | Most recent mx in year x-1 determines coverage type |
Opportunistic |
Definitions
Breast cancer | A first diagnosis of invasive carcinoma or ductal in-situ carcinoma of the breast (respectively C50 and D05 of ICD-O, third edition, version 10). |
Cancer detection rate | The number of breast cancers detected in a screening round per 1000 women screened. |
False-positive recall | Any recall for diagnostic assessment that was not followed by a screen-detected cancer. |
False-positive recall rate | The number of women with a False-positive recall per 1000 women screened. |
Initial screening | The first screening examination of individual women within the PMSP, regardless of how long the programme has been running |
Interval cancer | • Breast cancer that was diagnosed within 24 months of a negative screen. • Breast cancer that was diagnosed more than 3 months after the first diagnostic assessment that followed a positive screen (but at the latest within 24 months of screening). |
Interval cancer rate | The number of interval cancers diagnosed per 1000 women screened. |
Invitation coverage | The number of women that receive an invitation in year x, as a proportion of all women that should be invited in that year. |
Positive predictive value | The number of breast cancers detected per 100 women recalled for diagnostic assessment. |
Programme sensitivity | The number of screen-detected cancers as a proportion of all breast cancers discovered in the screened population within 2 years of screening |
Proportion of node-negative cancers | The number of node-negative cancers as a proportion of the total number of invasive screen-detected cancers |
Proportion of DCIS | The number of DCIS as a proportion of the total number of screen-detected cancers |
Proportion of stage ≥2 | The number of Stage II+ breast cancers as a proportion of the total number of screen-detected cancers |
Recall rate | The number of women recalled for diagnostic assessment per 100 women screened. |
Screen-detected cancer | Breast cancer that was diagnosed within 3 months of the first diagnostic assessment that followed a positive screen (but at the latest within 24 months of screening). |
Subsequent irregular screening | Any screening examination after the initial screening, where the most recent PMSP screening occurred > 30 months after the previous PMSP screening |
Subsequent regular screening | Any screening examination after the initial screening, where the most recent PMSP screening occurred <=30 months after the previous PMSP screening |
Statistical analysis
Results
Participation
Performance indicator [EU desirable target] | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | AAPC all years | APCb last segment | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% | (95% CI) | Yeara | % | (95% CI) | ||||||||||||||||
Target population 01/01, N |
692,964
|
699,472
|
707,645
|
717,956
|
728,628
|
739,449
|
751,171
|
763,832
|
778,866
|
799,767
|
816,921
|
830,455
|
843,110
|
854,612
|
861,223
| |||||
BC or Bilateral mastectomy, N |
13,569
|
15,886
|
18,248
|
19,989
|
20,833
|
21,689
|
22,522
|
22,985
|
23,400
|
23,935
|
24,680
|
25,220
|
25,810
|
26,226
|
26,474
| |||||
Eligible - refuses to be invited, N |
12,364
|
13,693
|
14,998
|
16,264
|
17,481
|
18,702
|
19,757
|
21,001
|
21,991
|
23,089
|
23,863
|
24,625
|
24,962
|
25,223
|
24,809
| |||||
Eligible - not to be invited this yearb, N |
45,207
|
171,528
|
198,729
|
227,791
|
255,135
|
314,695
|
279,757
|
333,516
|
335,365
|
360,949
|
371,003
|
370,777
|
380,358
|
386,578
|
390,457
| |||||
Eligible - to be invited this year, N |
621,824
|
498,365
|
475,670
|
453,912
|
435,179
|
384,363
|
429,135
|
386,330
|
398,110
|
391,794
|
397,375
|
409,833
|
411,980
|
416,585
|
419,483
| |||||
Invitations sent (invitation coverage), % | 22.0 | 33.1 | 41.5 | 50.4 | 68.0 | 68.9 | 76.1 | 85.0 | 88.9 | 93.2 | 93.1 | 94.0 | 95.1 | 95.7 | 96.0 | + 10.5b | (+ 8.3; + 12.8) | 2011 | + 0.4 | (−2.8; + 3.8) |
Eligible population 01/01, N |
679,395
|
683,586
|
689,397
|
697,967
|
707,795
|
717,760
|
728,649
|
740,847
|
755,466
|
775,832
|
792,241
|
805,235
|
817,300
|
828,386
|
834,749
| |||||
PMSP coverage, % | 17.9 | 24.8 | 30.9 | 35.0 | 39.4 | 43.1 | 44.0 | 45.4 | 45.8 | 47.4 | 48.4 | 48.4 | 48.3 | 48.9 | 50.0 | + 7.5b | (+ 6.5; + 8.6) | 2007 | + 1.6b | (+ 1.1; + 2.0) |
Opportunistic coverage, % | unknown | 21.3 | 20.5 | 20.2 | 20.3 | 19.9 | 19.2 | 18.3 | 17.7 | 17.2 | 16.8 | 16.0 | 15.3 | 14.8 | 14.1 | −3.0b | (−3.3; −2.6) | 2007 | −3.6b | (−3.3; −2.6) |
No coverage, % | 53.8 | 48.6 | 44.7 | 40.4 | 37.0 | 36.8 | 36.4 | 36.6 | 35.3 | 34.8 | 35.6 | 36.3 | 36.3 | 35.8 | −3.0b | (−3.5; −2.5) | 2012 | + 0.7 | (−0.4; + 1.8) | |
All invitations sent, N |
120,517
|
164,296
|
202,155
|
241,076
|
311,940
|
276,511
|
339,264
|
343,924
|
370,439
|
382,475
|
385,966
|
402,569
|
407,864
|
415,304
|
417,493
| |||||
Invitation Response Rate, % | 50.9 | 57.8 | 50.3 | 48.3 | 48.0 | 54.8 | 49.1 | 51.1 | 48.0 | 51.3 | 50.1 | 51.2 | 49.3 | 51.7 | 49.8 | −0.3 | (−0.9; + 0.4) | |||
All PMSP examinations, N |
103,909
|
119,861
|
127,714
|
134,772
|
164,075
|
165,873
|
176,133
|
183,175
|
183,810
|
203,326
|
199,899
|
209,809
|
204,540
|
218,723
|
218,118
| |||||
With BCR link, % | 80.0 | 83.3 | 98.7 | 98.9 | 98.6 | 98.9 | 98.7 | 98.9 | 99.0 | 99.4 | 99.4 | 99.5 | 99.6 | 99.7 | 99.8 | |||||
PMSP examinations with BCR link, N |
83,100
|
99,787
|
126,007
|
133,265
|
161,777
|
164,129
|
173,768
|
181,082
|
181,968
|
202,101
|
198,747
|
208,839
|
203,735
|
218,155
|
217,614
| |||||
mean age, years | 59.8 | 58.6 | 58.8 | 58.9 | 58.4 | 58.7 | 58.4 | 58.5 | 58.5 | 58.6 | 58.6 | 58.7 | 58.6 | 58.8 | 58.8 | |||||
initial screening, N |
83,100
|
89,385
|
62,149
|
46,728
|
55,899
|
44,823
|
40,562
|
42,923
|
38,995
|
40,506
|
40,961
|
36,852
|
37,497
|
38,454
|
38,851
| |||||
mean age, years | 59.8 | 58.4 | 56.2 | 57.1 | 55 | 54.7 | 54.2 | 53.5 | 53.5 | 53.2 | 53 | 52.7 | 52.7 | 52.6 | 52.8 | |||||
subsequent irregular screening, N |
12
|
16,138
|
15,935
|
21,479
|
19,179
|
15,886
|
16,714
|
17,911
|
18,950
|
17,676
|
17,207
|
16,863
|
19,490
|
21,045
| ||||||
mean age, years | 58.9 | 61.2 | 60.3 | 60.3 | 60.5 | 60.6 | 60.7 | 60.3 | 60.6 | 60.8 | 60.7 | 60.7 | 60.8 | 60.8 | ||||||
subsequent regular screening, N |
10,390
|
47,720
|
70,602
|
84,399
|
100,127
|
117,320
|
121,445
|
125,062
|
142,645
|
140,110
|
154,780
|
149,375
|
160,211
|
157,718
| ||||||
mean age, years | 60.1 | 61.2 | 59.8 | 60.2 | 60.2 | 59.6 | 59.9 | 59.8 | 59.8 | 60 | 60 | 59.9 | 60 | 60 | ||||||
Digital screening, % | 0.0 | 0.0 | 0.1 | 0.3 | 1.9 | 9.0 | 21.4 | 45.6 | 59.6 | 79.5 | 88.7 | 95.3 | 95.2 | 96.8 | 98.9 | |||||
Women recalled for diagnostic assessment, N |
4377
|
5598
|
5774
|
5859
|
7488
|
6322
|
7567
|
6706
|
6038
|
5932
|
6066
|
5328
|
5232
|
5183
|
5585
| |||||
Recall Rate, % | 5.3 | 5.6 | 4.6 | 4.4 | 4.6 | 3.9 | 4.4 | 3.7 | 3.3 | 2.9 | 3.1 | 2.6 | 2.6 | 2.4 | 2.6 | |||||
initial screens, % [< 5%] | 5.3 | 5.8 | 6 | 6.1 | 6.8 | 6.4 | 7.5 | 6.4 | 5.5 | 5.3 | 5.4 | 4.4 | 4.5 | 4.5 | 4.7 | −1.5b | (−2.9; −0.1) | 2008 |
−5.1
b
| (−6.9; −3.3) |
subsequent irregular screens, % | 3.6 | 4.6 | 4.5 | 4.1 | 4.9 | 4.2 | 3.8 | 3.1 | 3.8 | 3.2 | 3.4 | 3.2 | 3.4 | −2.9b | (−4.6; −1.1) | |||||
subsequent regular screens, % [< 3%] | 3.6 | 3.1 | 3.2 | 3.2 | 2.7 | 3.2 | 2.7 | 2.6 | 2.2 | 2.3 | 2 | 2 | 1.8 | 1.9 | −5.0b | (−6.0; − 3.9) | ||||
Screen detected cancers, N |
797
|
894
|
789
|
856
|
967
|
888
|
952
|
976
|
1018
|
1126
|
1153
|
1227
|
1123
|
1195
|
1190
| |||||
Cancer Detection Rate, ‰ | 9.6 | 9.0 | 6.3 | 6.4 | 6.0 | 5.4 | 5.5 | 5.4 | 5.6 | 5.6 | 5.8 | 5.9 | 5.5 | 5.5 | 5.5 | |||||
initial screens, ‰ | 9.6 | 9.2 | 7.2 | 8.0 | 7.4 | 6.6 | 7.1 | 6.5 | 6.3 | 6.5 | 6.3 | 5.8 | 5.6 | 6.4 | 6.3 | −0.6 | (−1.4; + 0.2) | |||
subsequent irregular screens, ‰ | 6.7 | 7.1 | 6.4 | 6.0 | 7.4 | 8.1 | 6.9 | 7.3 | 9.1 | 8.2 | 8.2 | 9.0 | 7.5 | + 2.1b | (+ 0.3; + 3.9) | |||||
subsequent regular screens, ‰ | 6.4 | 4.9 | 5.2 | 4.9 | 4.8 | 4.7 | 4.6 | 5.2 | 5.1 | 5.2 | 5.6 | 5.2 | 4.8 | 5.0 | 0.0 | (−1.1; + 1.1) | ||||
False-Positive Recalls, N |
3582
|
4704
|
4986
|
5003
|
6521
|
5434
|
6615
|
5730
|
5020
|
4806
|
4913
|
4101
|
4109
|
3988
|
4395
| |||||
False-Positive Recall Rate, ‰ | 43.1 | 47.1 | 39.6 | 37.5 | 40.3 | 33.1 | 38.1 | 31.6 | 27.6 | 23.8 | 24.7 | 19.6 | 20.2 | 18.3 | 20.2 | |||||
initial screens, ‰ | 43.1 | 49.1 | 52.8 | 53.4 | 60.4 | 57.7 | 67.7 | 57.9 | 49.1 | 46.2 | 47.7 | 38.5 | 39.7 | 38.1 | 40.3 | −1.4 | (−3.5; + 0.8) | 2007 |
−5.3
b
| (−7.4; − 3.1) |
subsequent irregular screens, ‰ | 29.6 | 39.3 | 38.6 | 34.9 | 41.5 | 33.8 | 31.2 | 24.0 | 29.0 | 23.9 | 25.7 | 22.6 | 26.2 | −4.0b | (−6.1; −1.9) | |||||
subsequent regular screens, ‰ | 29.2 | 25.7 | 26.6 | 27.4 | 21.8 | 27.4 | 22.1 | 20.4 | 17.4 | 17.5 | 14.7 | 14.6 | 13.0 | 14.4 | −6.1b | (−7.4; −4.9) | ||||
Positive predictive value, % | 18.2 | 16.0 | 13.6 | 14.6 | 12.9 | 14.0 | 12.6 | 14.6 | 16.9 | 19.0 | 19.0 | 23.0 | 21.5 | 23.1 | 21.3 | |||||
initial screens, % | 18.2 | 15.8 | 12.0 | 13.0 | 10.9 | 10.2 | 9.5 | 10.2 | 11.3 | 12.3 | 11.7 | 13.1 | 12.4 | 14.4 | 13.6 | + 0.1 | (−2.5; + 2.8) | 2006 |
+ 3.8
b
| (+ 1.5; + 6.1) |
subsequent irregular screening, % | 18.4 | 15.3 | 14.2 | 14.8 | 15.2 | 19.4 | 18.2 | 23.3 | 23.9 | 25.5 | 24.3 | 28.4 | 22.3 | + 5.0b | (+ 2.5; + 7.4) | |||||
Subsequent regular screening, % | 17.9 | 15.9 | 16.5 | 15.2 | 18.0 | 14.6 | 17.3 | 20.3 | 22.6 | 23.0 | 27.8 | 26.2 | 27.1 | 25.7 | + 3.8b | (+ 0.6; + 7.0) | 2013 | −2.1 | (−11.5; + 8.4) |
Recall rate & cancer detection
Interval cancers and sensitivity
Performance indicator [EU desirable target] | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | AAPC all years | APC last segment | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% | (95% CI) | Yeara | % | (95% CI) | ||||||||||||||||
All cancers (screen detected & interval cancers), N |
1071
|
1229
|
1147
|
1215
|
1407
|
1317
|
1450
|
1486
|
1543
|
1732
|
1702
|
1848
|
1726
| n.a. | ||||||
Screen detected cancers, N |
797
|
894
|
789
|
856
|
967
|
888
|
952
|
976
|
1018
|
1126
|
1153
|
1227
|
1123
|
1195
| ||||||
Programme sensitivity, % | 74.4 | 72.7 | 68.8 | 70.5 | 68.7 | 67.4 | 65.7 | 65.7 | 66.0 | 65.0 | 67.7 | 66.4 | 65.1 | |||||||
initial screens, % | 74.4 | 73.0 | 69.4 | 71.2 | 72.3 | 66.4 | 65.8 | 68.5 | 65.5 | 67.7 | 70.6 | 61.7 | 61.0 | −1.3b | (−2.4; −0.1) | 2012 | −6.5 | (− 13.3; + 0.8) | ||
subsequent irregular screens, % | 73.0 | 72.0 | 70.3 | 69.0 | 71.1 | 73.9 | 67.0 | 66.7 | 71.2 | 73.8 | 68.8 | −0.1 | (−1.5; + 1.3) | |||||||
subsequent regular screens, % | 68.8 | 65.9 | 69.3 | 65.0 | 67.7 | 64.5 | 62.7 | 66.0 | 63.8 | 66.1 | 66.6 | 65.6 | + 1.0 | (− 0.5; + 2.5) | 2005 | − 0.4 | (−1.2; + 0.5) | |||
Interval cancers, N |
274
|
335
|
358
|
359
|
440
|
429
|
498
|
510
|
525
|
606
|
549
|
621
|
603
| n.a. | ||||||
Diagnosed in first year after screening, % | 36.9 | 43.3 | 38.5 | 35.7 | 35.5 | 33.8 | 36.5 | 35.5 | 34.1 | 36.3 | 39.3 | 39.5 | 37.1 | −0.1 | (−1.3; + 1.1) | |||||
Diagnosed after positive screen, % | 22.3 | 21.5 | 17.0 | 12.3 | 16.6 | 14.0 | 16.3 | 12.9 | 10.3 | 11.7 | 10.0 | 10.5 | 9.6 | −6.4b | (−8.5; −4.2) | |||||
Interval cancer rate, ‰ | 3.3 | 3.4 | 2.8 | 2.7 | 2.7 | 2.6 | 2.9 | 2.8 | 2.9 | 3.0 | 2.8 | 3.0 | 3.0 | |||||||
initial screens, ‰ | 3.3 | 3.4 | 3.2 | 3.2 | 2.8 | 3.3 | 3.7 | 3.0 | 3.3 | 3.1 | 2.6 | 3.6 | 3.6 | + 1.5 | (−0.3; + 3.4) | |||||
subsequent irregular screens, ‰ | 2.5 | 2.8 | 2.7 | 2.7 | 3.0 | 2.9 | 3.4 | 3.6 | 3.7 | 2.9 | 3.7 | + 3.2b | (+ 0.3; + 6.1) | |||||||
subsequent regular screens, ‰ | 2.9 | 2.5 | 2.3 | 2.6 | 2.3 | 2.6 | 2.7 | 2.7 | 2.9 | 2.7 | 2.8 | 2.7 | + 0.5 | (−0.9; + 1.9) | ||||||
Characteristics screen detected cancers, initial screens | ||||||||||||||||||||
SDC total, N |
797
|
825
|
449
|
373
|
415
|
295
|
287
|
281
|
245
|
262
|
259
|
214
|
210
|
247
| ||||||
ductal carcinoma in-situ (DCIS), N |
140
|
132
|
72
|
59
|
75
|
50
|
58
|
53
|
41
|
64
|
35
|
48
|
35
|
44
| ||||||
invasive, N |
657
|
693
|
377
|
314
|
340
|
245
|
229
|
228
|
204
|
198
|
224
|
166
|
175
|
203
| ||||||
Stage, % | DCIS [10–20%] | 17.6 | 16.0 | 16.0 | 15.8 | 18.1 | 16.9 | 20.2 | 18.9 | 16.7 | 24.4 | 13.5 | 22.4 | 16.7 | 18.2 | −1.2 | (−3.2; + 0.9) | |||
Invasive SDC stage I | 40.7 | 45.0 | 46.3 | 48.8 | 47.0 | 46.4 | 42.2 | 44.1 | 48.2 | 42.7 | 48.6 | 52.3 | 43.8 | 42.9 | ||||||
Invasive SDC stage ≥II [< 30%] | 24.7 | 31.0 | 33.0 | 30.8 | 32.3 | 32.9 | 36.6 | 34.9 | 31.8 | 31.7 | 35.9 | 25.2 | 38.6 | 31.2 | + 1.9b | (+ 0.3; + 3.6) | ||||
Invasive SDC stage unknown | 17.1 | 8.0 | 4.7 | 4.6 | 2.7 | 3.7 | 1.0 | 2.1 | 3.3 | 1.1 | 1.9 | 0.0 | 1.0 | 7.7 | ||||||
Nodal status, % | Node - [> 70%] | 51.0 | 61.5 | 62.9 | 66.2 | 62.6 | 65.3 | 62.9 | 67.5 | 63.7 | 68.7 | 64.7 | 71.7 | 63.4 | 61.6 | + 1.7 | (−0.3; + 3.7) | 2004 | + 0.1 | (−0.8; + 1.1) |
Node + | 20.2 | 23.5 | 26.3 | 22.3 | 26.8 | 25.7 | 32.8 | 29.4 | 29.4 | 28.3 | 29.0 | 25.9 | 30.9 | 24.6 | ||||||
Unknown (invasive SDC) | 28.8 | 15.0 | 10.9 | 11.5 | 10.6 | 9.0 | 4.4 | 3.1 | 6.9 | 3.0 | 6.3 | 2.4 | 5.7 | 13.8 | ||||||
Characteristics screen detected cancers, subsequent irregular screens | ||||||||||||||||||||
SDC total, N |
3
|
108
|
113
|
137
|
116
|
118
|
136
|
124
|
138
|
161
|
141
|
139
|
175
| |||||||
ductal carcinoma in-situ (DCIS), N |
0
|
15
|
11
|
15
|
21
|
17
|
21
|
21
|
23
|
28
|
19
|
20
|
25
| |||||||
invasive, N |
3
|
93
|
102
|
122
|
95
|
101
|
115
|
103
|
115
|
133
|
122
|
119
|
150
| |||||||
Stage, % | DCIS | 13.9 | 9.7 | 10.9 | 18.1 | 14.4 | 15.4 | 16.9 | 16.7 | 17.4 | 13.5 | 14.4 | 14.9 | + 3.5 | (−1.1; + 8.4) | |||||
Invasive SDC stage I | 56.5 | 62.8 | 51.8 | 46.6 | 47.5 | 53.7 | 46.0 | 49.3 | 54.7 | 61.7 | 54.0 | 56.6 | ||||||||
Invasive SDC stage ≥II | 25.0 | 23.9 | 35.8 | 31.9 | 37.3 | 29.4 | 33.1 | 33.3 | 28.0 | 24.1 | 31.7 | 24.6 | + 2.6 | (−4.5; + 10.2) | 2007 | −5.1 | (−10.6; + 0.8) | |||
Invasive SDC stage unknown | 4.6 | 3.5 | 1.5 | 3.4 | 0.8 | 1.5 | 4.0 | 0.7 | 0.0 | 0.7 | 0.0 | 4.0 | ||||||||
Nodal status, % | Node (−) | 68.8 | 73.5 | 63.9 | 65.3 | 69.3 | 72.2 | 61.2 | 70.4 | 72.2 | 77.0 | 70.6 | 66.0 | −0.0 | (−1.6; + 1.6) | |||||
Node (+) | 21.5 | 17.6 | 27.0 | 26.3 | 28.7 | 22.6 | 32.0 | 26.1 | 24.8 | 18.9 | 26.9 | 22.0 | ||||||||
Unknown (invasive SDC) | 9.7 | 8.8 | 9.0 | 8.4 | 2.0 | 5.2 | 6.8 | 3.5 | 3.0 | 4.1 | 2.5 | 12.0 | ||||||||
Characteristics screen detected cancers, subsequent regular screens | ||||||||||||||||||||
SDC total, N |
66
|
232
|
370
|
415
|
477
|
547
|
559
|
649
|
726
|
733
|
872
|
774
|
773
| |||||||
ductal carcinoma in-situ (DCIS), N |
10
|
36
|
70
|
78
|
83
|
95
|
91
|
93
|
106
|
110
|
141
|
120
|
106
| |||||||
invasive, N |
56
|
196
|
300
|
337
|
394
|
452
|
468
|
556
|
620
|
623
|
731
|
654
|
667
| |||||||
Stage, % | DCIS [10–20%] | 15.2 | 15.5 | 18.9 | 18.8 | 17.4 | 17.4 | 16.5 | 14.5 | 14.6 | 15.0 | 16.2 | 16.1 | 14.0 | + 2.5 | (−1.6; + 6.8) | ||||
Invasive SDC stage I | 60.6 | 52.2 | 45.7 | 52.8 | 52.8 | 52.1 | 51.9 | 56.5 | 56.5 | 54.4 | 56.9 | 56.7 | 55.2 | |||||||
Invasive SDC stage ≥II [< 25%] | 21.2 | 30.2 | 31.9 | 24.3 | 27.0 | 29.3 | 30.2 | 27.4 | 27.8 | 29.9 | 26.1 | 26.6 | 24.8 | −0.9 | (−2.2; + 0.5) | |||||
Invasive SDC stage unknown | 3.0 | 2.2 | 3.5 | 4.1 | 2.7 | 1.3 | 1.4 | 1.5 | 1.1 | 0.7 | 0.8 | 0.5 | 6.0 | |||||||
Nodal status, % | Node (−) [> 75%] | 76.8 | 63.8 | 64.0 | 65.6 | 71.6 | 71.5 | 71.4 | 71.9 | 73.5 | 72.7 | 74.8 | 74.8 | 65.4 | + 0.1 | (−1.3; + 1.5) | ||||
Node (+) | 16.1 | 25.5 | 25.7 | 22.0 | 22.6 | 23.2 | 25.2 | 23.9 | 23.2 | 24.2 | 22.4 | 21.7 | 23.4 | |||||||
Unknown (invasive SDC) | 7.1 | 10.7 | 10.3 | 12.5 | 5.8 | 5.3 | 3.4 | 4.1 | 3.2 | 3.0 | 2.7 | 3.5 | 11.2 |